Exelixis

Oncology-focused biopharmaceutical company developing cancer treatments.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New drug XB010 takes on advanced cancers in first human trial Results expected Nov 2026 (estimated)
• Can a drug combo outperform standard therapy for a rare kidney cancer? Results expected Dec 2026 (estimated)
• New drug combo aims to shrink hard-to-treat tumors Results expected Jan 2027 (estimated)
• New hope for Hard-to-Treat cancers? early trial launches Results expected May 2027 (estimated)